IGM Biosciences Inc
NASDAQ:IGMS

  • LAST PRICE
    10.4300
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    10.4600/ 1
  • Ask / Lots
    15.0000/ 1
  • Open / Previous Close
    --- / 10.4300
  • Day Range
    ---
  • 52 Week Range
    4.7200
    22.5000
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
IGMS
IGM Biosciences Inc
562.5M
-2.9x
---
ANNX
Annexon Inc
563.9M
-5.1x
---
OLMA
Olema Pharmaceuticals Inc
556.9M
-4.6x
---
SANA
Sana Biotechnology Inc
547.0M
-1.8x
---
HUMA
Humacyte Inc
543.3M
-3.3x
---
PROK
ProKidney Corp
539.6M
-3.3x
---
As of 2024-11-29

Company Information

IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.

Contact Information

Headquarters
325 E Middlefield RdMOUNTAIN VIEW, CA, United States 94043-4003
Phone
650-965-7873
Fax
302-655-5049

Executives

Head - Research and Autoimmunity
Mary Harler
Chief Financial Officer
Misbah Tahir
Chief Business Officer
Lisa Decker
Independent Director
Felix Baker
Independent Director
M. Kathleen Behrens

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$562.5M
Revenue (TTM)
$2.9M
Shares Outstanding
59.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.10
EPS
$-3.65
Book Value
$3.46
P/E Ratio
-2.9x
Price/Sales (TTM)
192.8
Price/Cash Flow (TTM)
---
Operating Margin
-8,043.83%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.